home > ict > autumn 2019 > the spirit of radical integration
International Clinical Trials

The Spirit of Radical Integration

Patricia Leuchten, Founder and CEO of The Avoca Group, asked people at a recent pharmaceutical industry conference to raise their hands if they felt their company was ‘pretty good’ − not great, just pretty good − at dealing with the risks inherent in the clinical trial process.

Not a single hand went up.

Her goal is to one day ask again and see every hand raised. Leuchten’s passion, and Avoca’s mission, is for an industry that now struggles to manage risks and design quality into clinical trials to develop a more proactive mindset and overcome communication gaps in bringing life-changing products to patients. As she puts it, “It’s the difference between putting out fires and preventing fires”. Clinical trials are, of course, never free of risks, especially with increasingly complex therapies, trial designs, and operating models. They all contain elements of the unknown that no amount of preparation can completely erase. However, risks can be proactively identified, managed, and mitigated, and that’s where Avoca comes in.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the company

The Avoca Group is a life science consulting firm dedicated to improving quality and compliance in clinical trial execution. Since 2011, the AQC, a collaborative of over 100 pharma, biotech, CRO, and clinical service provider companies, has led the industry in developing practical solutions for improving quality and execution in clinical trials. Companies benefit from Avoca’s insightful research, deep subject matter expertise, industry-leading approaches, and technology. Avoca offers platforms and tailored solutions to help clinical research companies increase quality, ensure compliance, and improve efficiency so that medicines can reach patients faster.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Recursion Announces Transformational Collaboration with Roche and Genentech in Neuroscience and Oncology, Advancing Novel Medicines to Patients Using Machine Learning and High Content Screening Methods at Scale to Map Complex Biology

The deal, worth several billion dollars, is a future-looking model of technology-enabled target and drug discovery
More info >>

White Papers



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement